Multiple Sclerosis

A trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.

Cladribine shows superior efficacy over S1P modulators in reducing disability progression in treatment-naive relapsing-remitting MS patients.

Findings from a second phase 3 trial, dubbed FENhance 1, assessing fenebrutinib in patients with relapsing multiple sclerosis are anticipated by the first half of 2026.

Obexelimab shows promising results in reducing lesions in relapsing multiple sclerosis, highlighting its potential as a new treatment for autoimmune diseases.

Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, lead investigator of the phase 3 ORATORIO-HAND trial, provided comment on the results presented at ECTRIMS 2025, highlighting ocrelizumab’s therapeutic benefit in more advanced forms of multiple sclerosis.

Robert Shin, MD, FAAN, professor of neurology and ophthalmology at the University of Virginia and director of the UVA MS and Clinical Neuroimmunology Center, recently shared his expertise on how multiple sclerosis (MS) affects men on the National MS Society’s Ask an MS Expert program.

Experts shared their clinical perspectives on trending topics in the treatment and management of multiple sclerosis at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

Riley Bove, MD, an associate professor of neurology at UCSF, breaks down the ARTIOS phase 3b trial results, highlighting the exceptionally low relapse rates, MRI outcomes, and safety findings in patients switching therapies.

At ECTRIMS 2025, a staff neurologist at Cleveland Clinic discussed findings from an observational study on long-term safety risks of ocrelizumab in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

In episode 1, Bove explores how ofatumumab, a B-cell–depleting therapy, stands apart from fingolimod and fumarates, and why its mechanism may offer distinct treatment advantages.

At ECTRIMS 2025, the postdoctoral research fellow at the University of Siena in Italy talked about how machine learning could classify multiple sclerosis into biologically distinct subtypes. [WATCH TIME: 5 minutes]

In a phase 3 trial presented at ECTRIMS 2025, ocrelizumab demonstrated noninferior relapse control compared with fingolimod in pediatric patients with relapsing-remitting multiple sclerosis.

Primary results presented at ECTRIMS 2025 suggest that body-weight–adjusted high-dose of ocrelizumab did not further slow disease progression in patients with primary progressive multiple sclerosis.

A phase 2 study presented at ECTRIMS 2025 showed that autologous adipose-derived mesenchymal stem cell therapy was safe and effective in patients with relapsing-remitting multiple sclerosis.

At ECTRIMS 2025, the associate professor of neurology at Yale School of Medicine talked about the 2024 diagnostic criteria, the preclinical phase of the disease, and progressive MS. [WATCH TIME: 3 minutes]

New research highlights the effectiveness of paramagnetic rim lesions as a key biomarker for diagnosing multiple sclerosis, enhancing diagnostic accuracy.

At ECTRIMS 2025, the professor of neurology at the University of Basel talked about the decades of progress in MS therapeutics and highlighted the need for comprehensive, early assessments for patients. [WATCH TIME: 4 minutes]

New data reveal vidofludimus calcium shows promise in slowing disability progression in primary progressive multiple sclerosis, warranting further trials.

At ECTRIMS 2025, experts discussed using AI-powered unstructured data processing to enhance understanding of drug efficacy, safety, and patient outcomes in multiple sclerosis. [WATCH TIME: 3 minutes]

In a head-to-head phase 3 trial presented at ECTRIMS 2025, rituximab was noninferior to cladribine in preventing new or enlarging MRI lesions in relapsing-remitting multiple sclerosis.

In a late-breaking presentation at ECTRIMS 2025, findings showed that annual administration of rituximab was noninferior in efficacy to the 6-monthly treatment for relapsing-remitting multiple sclerosis.

At ECTRIMS 2025, the professor of neurology at Karolinska Institutet provided clinical insights on results from the phase 3 RIDOSE-MS trial of yearly rituximab in relapsing-remitting multiple sclerosis. [WATCH TIME: 5 minutes]

At ECTRIMS 2025, the interim chief executive officer at the Consortium of Multiple Sclerosis Centers discussed recent progress in multiple sclerosis for treatment and diagnosis. [WATCH TIME: 5 minutes]

Tiziana Life Sciences presents the design a phase 2a trial of nasal foralumab for treating nonactive secondary progressive MS at ECTRIMS 2025.

Tolebrutinib shows promise in improving quality of life for patients with nonrelapsing secondary progressive multiple sclerosis, according to recent trial findings.